VALACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES
The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam.
1 - 18 . (canceled)
19 . A method to treat a subject susceptible to or afflicted with fibromyalgia, the method comprising administering to the subject a therapeutically-effective co-acting combination of valaciclovir and meloxicam, wherein each of valaciclovir and meloxicam is administered in an amount in combination effective to treat fibromyalgia.
20 . The method of claim 19 wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 3000 mg, and wherein the amount of meloxicam is administered in a unit dose in a range of about 7.5 mg to about 30 mg.
21 . The method of claim 20 , wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 1500 mg, and wherein the amount of meloxicam is administered in a unit dose in a range of about 7.5 mg to about 15 mg.
22 . The method of claim 21 , wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 1000 mg.
23 . The method claim 20 , wherein the amount of valaciclovir is administered in a unit dose of about 750 mg, about 1000 mg, about 1250 mg, or about 1500 mg, and wherein the amount of meloxicam is administered in a unit dose of about 7.5 mg, about 15 mg or about 30 mg.
24 . The method of claim 22 , wherein a unit dose of valaciclovir is administered two or three times per day, and wherein a unit dose of meloxicam is administered two or three times per day.
25 . A method to treat a subject susceptible to or afflicted with one or more functional somatic syndrome conditions selected from the group consisting of fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, chronic pain, chronic headache, chronic neck pain, chronic back pain, chronic depression, chronic clinical anxiety disorder, posttraumatic stress disorder (PTSD), brain fog, cognitive dysfunction and chronic interstitial cystitis, the method comprising administering to the subject a therapeutically-effective co-acting combination of valaciclovir and meloxicam, wherein each of valaciclovir and meloxicam is administered in an amount in combination effective to treat one or more functional somatic syndrome conditions.
26 . The method of claim 25 wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 3000 mg, and wherein the amount of meloxicam is administered in a unit dose in a range of about 7.5 mg to about 30 mg.
27 . The method of claim 26 , wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 1500 mg, and wherein the amount of meloxicam is administered in a unit dose in a range of about 7.5 mg to about 15 mg.
28 . The method of claim 27 , wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 1000 mg.
29 . The method claim 26 , wherein the amount of valaciclovir is administered in a unit dose of about 750 mg, about 1000 mg, about 1250 mg, or about 1500 mg, and wherein the amount of meloxicam is administered in a unit dose of about 7.5 mg, about 15 mg, or about 30 mg.
30 . The method of claim 28 , wherein a unit dose of valaciclovir is administered two or three times per day, and wherein a unit dose of meloxicam is administered two or three times per day.
31 . The method of claim 25 , wherein the functional somatic syndrome condition is a combination of fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome, coexistent in the subject.
32 . The method of claim 25 , wherein the functional somatic syndrome condition is a combination of fibromyalgia and irritable bowel syndrome, coexistent in the subject.
33 . The method of claim 25 , wherein the functional somatic syndrome condition is a combination of fibromyalgia and chronic fatigue syndrome, coexistent in the subject.
34 . A method to treat a subject susceptible to or afflicted with irritable bowel syndrome or chronic fatigue syndrome, the method comprising administering to the subject a therapeutically-effective co-acting combination of valaciclovir and meloxicam, wherein each of valaciclovir and meloxicam is administered in an amount in combination effective to treat irritable bowel syndrome or chronic fatigue syndrome.
35 . The method of claim 34 wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 3000 mg, and wherein the amount of meloxicam is administered in a unit dose in a range of about 7.5 mg to about 30 mg.
36 . The method of claim 35 , wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 1500 mg, and wherein the amount of meloxicam is administered in a unit dose in a range of about 7.5 mg to about 15 mg.
37 . The method of claim 36 , wherein the amount of valaciclovir is administered in a unit dose in a range of about 750 mg to about 1000 mg.
38 . The method claim 35 , wherein the amount of valaciclovir is administered in a unit dose of about 750 mg, about 1000 mg, about 1250 mg, or about 1500 mg, and wherein the amount of meloxicam is administered in a unit dose of about 7.5 mg, about 15 mg, or about 30 mg.
39 . The method of claim 37 , wherein a unit dose of valaciclovir is administered two or three times per day, and wherein a unit dose of meloxicam is administered two or three times per day.
40 . A drug-combination comprising valaciclovir and meloxicam, wherein valaciclovir and meloxicam are each present in a co-acting chronic-disease-treatment-effective amount.
41 . The drug-combination of claim 40 , wherein valaciclovir and meloxicam are each present in a co-acting functional-somatic-syndrome-condition-treatment-effective amount.
42 . The drug-combination of claim 41 , wherein valaciclovir and meloxicam are each present in a co-acting fibromyalgia-treatment-effective amount.
43 . The drug-combination of claim 40 , wherein valaciclovir is present in an amount in a range of about 750 mg to about 3000 mg, and wherein meloxicam is present in an amount in a range of about 7.5 mg to about 30 mg.
44 . The drug-combination of claim 43 , wherein valaciclovir is present in an amount in a range of about 750 mg to about 1500 mg, and wherein meloxicam is present in an amount in a range of about 7.5 mg to about 15 mg.
45 . The drug-combination of claim 44 , wherein valaciclovir is present in an amount in a range of about 750 mg to about 1000 mg.
46 . The drug-combination of claim 43 , wherein valaciclovir is present in an amount of about 750 mg, about 1000 mg, about 1250 mg, or about 1500 mg, and wherein meloxicam is present in an amount of about 7.5 mg, about 15 mg, or about 30 mg.